PRIMAXIN I.M. SUMMARY
PRIMAXIN I.M. (Imipenem and Cilastatin for Injectable Suspension) is a formulation of imipenem (a thienamycin antibiotic) and cilastatin sodium (the inhibitor of the renal dipeptidase, dehydropeptidase I). PRIMAXIN I.M. is a potent broad spectrum antibacterial agent for intramuscular administration.
PRIMAXIN I.M. is indicated for the treatment of serious infections (listed below) of mild to moderate severity for which intramuscular therapy is appropriate. PRIMAXIN I.M. is not intended for the therapy of severe or life-threatening infections, including bacterial sepsis or endocarditis, or in instances of major physiological impairments such as shock.
PRIMAXIN I.M. is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below:
- Lower respiratory tract infections, including pneumonia and bronchitis as an exacerbation of COPD, caused by
- Intra-abdominal infections, including acute gangrenous or perforated appendicitis and appendicitis with peritonitis, caused by Group D streptococcus including
Enterococcus faecalis * ; Streptococcus viridans
group * ;
Escherichia coli; Klebsiella pneumoniae * ; Pseudomonas aeruginosa * ; Bacteroides
B. fragilis, B. distasonis * , B. intermedius *
B. thetaiotaomicron * ; Fusobacterium
- Skin and skin structure infections, including abscesses, cellulitis, infected skin ulcers and wound infections caused by
including penicillinase-producing strains; Streptococcus pyogenes * ;
Group D streptococcus including
Enterococcus faecalis; Acinetobacter
species * including
A. calcoaceticus, * ; Citrobacter
species * ;
Escherichia coli; Enterobacter cloacae; Klebsiella pneumoniae * ; Pseudomonas aeruginosa *
species * including
B. fragilis * .
- Gynecologic infections, including postpartum endomyometritis, caused by Group D streptococcus including
Enterococcus faecalis * ; Escherichia coli; Klebsiella pneumoniae * ; Bacteroides intermedius * ;
species * .
As with other beta-lactam antibiotics, some strains of
may develop resistance fairly rapidly during treatment with PRIMAXIN I.M. During therapy of
infections, periodic susceptibility testing should be done when clinically appropriate.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of PRIMAXIN I.M. and other antibacterial drugs, PRIMAXIN I.M. should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
*Efficacy for this organism in this organ system was studied in fewer than 10 infections.
Published Studies Related to Primaxin I.M. (Imipenem / Cilastatin)
Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. [2010.11]
Imipenem/cilastatin and meropenem are carbapenem antibiotics that are infused intravenously (IV) over 30 to 45 min...
Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. [2010.07.21]
BACKGROUND: Tigecycline, a first-in-class broad-spectrum glycylcycline antibiotic, has broad-spectrum in vitro activity against bacteria commonly encountered in complicated intra-abdominal infections (cIAIs), including aerobic and facultative Gram-positive and Gram-negative bacteria and anaerobic bacteria. In the current trial, tigecycline was evaluated for safety and efficacy vs. imipenem/cilastatin in hospitalized Chinese patients with cIAIs... CONCLUSIONS: Clinical cure rates for tigecycline were consistent with those found in global cIAI studies. The overall safety profile was also consistent with that observed in global studies of tigecycline for treatment of cIAI, as well as that observed in analyses of Chinese patients in those studies; no novel trends were observed. TRIAL REGISTRATION: ClinicalTrials.gov NCT00136201.
Population Pharmacokinetics and Pharmacodynamics of Continuous vs. Short-Term Infusion of Imipenem/Cilastatin in Critically Ill Patients: A Randomized, Controlled Trial. [2007.07.09]
Beta-lactams are regularly administered as intermittent short-term infusions. The time that free drug concentrations exceed the minimal inhibitory concentration (fT>MIC) is the measure of drug exposure that best correlates with clinical outcome for beta-lactams... Larger clinical trials are warranted for evaluation of continuous infusions at a reduced dose of imipenem in critically ill patients.
Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia. 
CONCLUSION: These results suggest that sulbactam/ampicillin therapy has excellent efficacy and tolerability and that it may be highly effective, even in severe cases of pneumonia. This regimen may thus serve as first-line treatment for the treatment of community-acquired pneumonia in elderly patients.
Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. [2005.09]
BACKGROUND: Meropenem, a broad-spectrum carbapenem with potent in vitro activity, is postulated to be an effective monotherapy for the treatment of complicated skin and skin structure infections (cSSSI)... CONCLUSION: In one of the largest studies conducted to date of hospitalized patients with cSSSI, meropenem, 500 mg IV q8h had comparable safety and efficacy to imipenem-cilastatin, 500 mg IV q8h.
Clinical Trials Related to Primaxin I.M. (Imipenem / Cilastatin)
Complicated Skin and Skin Structure Infections [Completed]
The purpose of this study is to demonstrate the non-inferiority of meropenem (Merrem) and
imipenem in hospitalised subjects with complicated skin and skin structure infections.
GSK2251052 in Complicated Urinary Tract Infection [Recruiting]
This study is being conducted to evaluate the safety, efficacy (clinical and
microbiological), pharmacokinetics/pharmacodynamics of GSK2251052 and to assess whether it
would be a suitable antibiotic for the treatment for febrile lower cUTI and
pyelonephritis(complicated and uncomplicated). GSK2251052 will be compared to
imipenem-cilastatin, which is an antibiotic commonly used to treat serious cUTI infections.
GSK2251052 has a spectrum of microbiological activity that includes pathogens responsible
A Study of the Safety and Effectiveness of Doripenem in the Treatment of Patients With Ventilator-associated Pneumonia [Recruiting]
The purpose of the study is to show that doripenem is as effective as imipenem-cilastatin in
the treatment of patients with ventilator-associated pneumonia. The study population will
include hospitalized patients who have a diagnosis of ventilator-associated pneumonia.
A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005 AM1) [Recruiting]
Part I of this study will compare the pharmacokinetics of MK-7655, dosed in combination with
PRIMAXIN® (imipenem + cilastatin), in participants with impaired renal function and matched
control participants. In Part II of the study, the potential for renal insufficiency to
affect non-renal clearance mechanisms will be investigated.
Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli [Recruiting]
Approximately 444 subjects who are greater than or equal to 18 to 95 years of age, are
non-pregnant, and are in the inpatient setting of one of the six study sites will be
evaluated to treatment efficacy. Analysis will include subjects with bloodstream infection
(BSI) or pneumonia due to at least one of the following gram-negative bacilli organisms:
Acinetobacter baumannii, Klebsiella spp, Escherichia coli, Enterbactor spp. and/or
Pseudomonas aeruginosa that demonstrates in vitro non-susceptibility defined as extensively
drug-resistant Gram-negative bacilli (XDR-GNB) which includes XDR-AB, XDR-PA and CRE. If a
subject has both BSI and pneumonia at the time of study enrollment, they will be included as
a subject with pneumonia.
â€¢Determine whether the treatment regimen of Colistimethate sodium (colistin) combined with
Imipenem-cilistatin (imipenem) is associated with a decreased risk for mortality compared to
colistin alone for patients with bloodstream infection (BSI) and/or pneumonia due to
â€¢Determine what treatment regimen (colistin monotherapy or colistin combined with imipenem)
is more likely to reduce the emergence of colistin resistance among XDR-GNB isolates during
Page last updated: 2011-12-09